img

Rep Nicole Malliotakis says US self-sufficiency is a ‘national security issue’

“This is so critical. If we learned anything from COVID, we can’t rely on other countries, particularly Communist China."

ADVERTISEMENT

“This is so critical. If we learned anything from COVID, we can’t rely on other countries, particularly Communist China."

ADVERTISEMENT

Representative Nicole Malliotakis (R-NY) is speaking out about the need for the US to become "self-sufficient" in its supply chains for national security reasons, particularly in regard to the pharmaceutical industry.

Malliotakis appeared on Fox Business where she criticized the Biden administration for failing to bring pharmaceutical and medical manufacturing back to the US after the COVID-19 pandemic. She added that she hopes President Donald Trump will act differently and address this issue.

“This is so critical. If we learned anything from COVID, we can’t rely on other countries, particularly Communist China,” Malliotakis said.

“We’re working to get something in the tax package that would actually jumpstart domestic manufacturing for pharmaceuticals, for medical supply chain,” she added. “I believe President Trump is going to do it, and we need to do it… we got to be self-sufficient. It’s a national security issue.”



Malliotakis is working to push through an investment tax credit for manufacturing facilities that open in the US. The move follows concerns over supply chain vulnerabilities that intensified during the pandemic, when the US faced shortages due to its reliance on China, especially with medical equipment. Trump has consistently pushed for increased domestic manufacturing to reduce dependency on foreign nations. 

As the Trump administration has made it a priority to implement policy changes that incentivize domestic manufacturing, including issuing sweeping tariffs on foreign goods, large pharmaceutical companies seem to be planning accordingly. Last month, pharmaceutical giant Eli Lilly recently announced plans to invest $27 billion in four new US manufacturing sites. The company’s CEO, David Ricks, explained that the move represents “the largest pharmaceutical expansion investment in US history.”

ADVERTISEMENT
ADVERTISEMENT
Sign in to comment

Comments

Dean

What is wrong with her face?

Powered by The Post Millennial CMS™ Comments

Join and support independent free thinkers!

We’re independent and can’t be cancelled. The establishment media is increasingly dedicated to divisive cancel culture, corporate wokeism, and political correctness, all while covering up corruption from the corridors of power. The need for fact-based journalism and thoughtful analysis has never been greater. When you support The Post Millennial, you support freedom of the press at a time when it's under direct attack. Join the ranks of independent, free thinkers by supporting us today for as little as $1.

Support The Post Millennial

Remind me next month

To find out what personal data we collect and how we use it, please visit our Privacy Policy

ADVERTISEMENT
ADVERTISEMENT
By signing up you agree to our Terms of Use and Privacy Policy
ADVERTISEMENT
© 2025 The Post Millennial, Privacy Policy | Do Not Sell My Personal Information